FdaNdcDirectoryPulse / compare
BRYTLY vs Guaifenesin: FdaNdcDirectoryPulse comparison
BRYTLY (2026-10-16) and Guaifenesin (2026-10-27) are peer FdaNdcDirectoryPulse records.
Data as of · Compiled by Zalwin from U.S. FDA National Drug Code (NDC) Directory via openFDA
Both records plus every comparable record, with all columns and source links · Card, Apple Pay, Google Pay or Link via Stripe
How does BRYTLY compare to Guaifenesin?
| Field | BRYTLY | Guaifenesin |
|---|---|---|
| Product | BRYTLY | Guaifenesin |
| Generic name | Apraclonidine Hydrochloride | Guaifenesin |
| NDC | 0065-8596 | 57483-144 |
| Labeler | Alcon Laboratories, Inc. | INNOVUS PHARMACEUTICALS, INC. |
| Product type | HUMAN OTC DRUG | HUMAN OTC DRUG |
| Approval pathway | NDA | ANDA |
| Application number | NDA220341 | ANDA210453 |
| Dosage form | SOLUTION/ DROPS | TABLET, EXTENDED RELEASE |
| Route | OPHTHALMIC | ORAL |
| Active ingredients | APRACLONIDINE HYDROCHLORIDE 1.25 mg/mL | GUAIFENESIN 1200 mg/1 |
| Marketing start | 2026-10-16 | 2026-10-27 |
| Package configurations | 3 | 1 |
| Launch Signal Score | 45/100 | 40/100 |
| Peer rank and all 500 records (CSV) | 🔒 Click to unlock → | |
| Official source URLs for every peer record | 🔒 Click to unlock → | |
Official records: BRYTLY · Guaifenesin
Get new listings in your categories
FdaNdcDirectoryPulse emails new drug listings matching your pathway and product type.
Listing data comes from the FDA NDC directory via openFDA; a listing is not an FDA approval or endorsement and may be updated or withdrawn. Informational only; not medical advice.